作者:Gülhan Turan-Zitouni、Mehlika Dilek Altıntop、Ahmet Özdemir、Zafer Asım Kaplancıklı、Gülşen Akalın Çiftçi、Halide Edip Temel
DOI:10.1016/j.ejmech.2015.11.002
日期:2016.1
can be identified as the most promising anticancer agent due to its notable inhibitory effects on A549 and C6 cell lines and low toxicity to NIH/3T3 cell lines. Compound 5 exhibited anticancer activity against A549 and C6 cell lines with IC50 values of 37.3 ± 6.8 μg/mL and 11.3 ± 1.2 μg/mL, whereas mitoxantrone showed anticancer activity against A549 and C6 cell lines with IC50 values of 15.7 ± 4.0 μg/mL
通过1,1'-(3,3'-二甲氧基联苯-4,4'-二基)双(硫脲)与苯甲酰溴的闭环合成了新的双噻唑衍生物(1-10),并评估了它们的细胞毒性作用MTT法检测A549人肺腺癌,C6大鼠神经胶质瘤,5RP7 H-ras致癌基因转化的大鼠胚胎成纤维细胞和NIH / 3T3小鼠胚胎成纤维细胞系的表达。研究了这些化合物的DNA合成抑制作用。还使用改良的Ellman分光光度法评估了每种衍生物抑制AChE和BuChE的能力。在这些化合物中,3,3'-二甲氧基-N(4),N(4)'-双(4-(4-溴苯基)噻唑-2-基)-[1,1'-联苯] -4,4 ' -二胺(5)因其对A549和C6细胞系的显着抑制作用以及对NIH / 3T3细胞系的低毒性而被认为是最有前途的抗癌剂。化合物5对A549和C6细胞系表现出抗癌活性,IC50值为37.3±6.8μg/ mL和11.3±1.2μg/ mL,而米托蒽醌对A549